
G-NiiB formulates new synbiotics to tackle Asia’s growing MAFLD
Microbiome specialist firm G-NiiB’s latest launch is a synbiotic clinically shown to reduce fatty liver and liver stiffness, against the backdrop of growing MAFLD prevalence across Asia.



